Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The importance of proteomics in myeloma and how this may be implemented in clinical practice

Arun Wiita • 29 Sep 2023
IMS 2023
Multiple Myeloma

Arun Wiita, MD, PhD, University of California, San Francisco, CA, discusses how characterizing the myeloma cell surface proteome for different patient populations can lead to the identification of novel immunotherapeutic targets and markers of resistance in myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding: Roche/Genentech

More from Arun Wiita

1:37
Addressing proteasome inhibitor resistance in multiple myeloma in the immunotherapy era
Arun Wiita • 29 Sep 2023
1:46
Insights into mass spectrometry-based proteomics in multiple myeloma research
Arun Wiita • 29 Sep 2023
2:29
The impact of allosteric HSP70 inhibitors on proteasome inhibitor resistance in multiple myeloma
Arun Wiita • 26 Sep 2022
3:05
Identifying new therapeutic targets on the surfaceome of myeloma plasma cells with proteomics
Arun Wiita • 26 Aug 2022

Related Videos

1:15
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy • 28 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals